EMA panel backs Alvotech’s AVT06; EU approval now in sight

Rhea-AI Filing Summary

Alvotech (NASDAQ: ALVO) has furnished a Form 6-K to report a key regulatory milestone. The filing highlights that on 23 June 2025 the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). AVT06 targets retinal diseases treated by the USD-billion blockbuster reference product and, if approved, would significantly broaden Alvotech’s commercial portfolio in ophthalmology.

The Form 6-K notes that Exhibit 99.1 (the detailed press release) is being furnished—not filed—and therefore is not subject to Exchange Act Section 18 liabilities. Excluding that exhibit, the report is incorporated by reference into Alvotech’s shelf registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111, 333-281684) and its Form S-8 (File No. 333-266881), maintaining the company’s ability to raise capital under those documents.

A CHMP positive opinion is typically the final step before the European Commission grants marketing authorisation, implying a potential near-term launch opportunity, although the Commission’s decision and commercial timelines are not disclosed in this filing. No financial metrics, sales forecasts, or partnership details are provided.

Positive

• CHMP positive opinion for AVT06 significantly advances the biosimilar toward European marketing authorisation.
• Diversification: AVT06 expands Alvotech’s pipeline into ophthalmology, complementing existing therapeutic areas.
• Regulatory momentum reduces approval risk and could support valuation and fundraising under existing shelf registrations.

Negative

• Final EMA approval is still pending, leaving timing and commercial launch uncertain.
• No financial projections or partnership details were provided, limiting visibility into revenue potential and margin impact.

Insights

Biopharma Analyst

TL;DR: CHMP positive opinion materially de-risks AVT06 and accelerates Alvotech’s entry into the high-value aflibercept biosimilar market.

Regulatory: A CHMP endorsement historically precedes formal European Commission approval within ~60 days, reducing regulatory risk for AVT06. Product fit: Eylea® generated multi-billion-dollar sales for Bayer/Regeneron; a biosimilar unlocks a sizeable addressable market once EU patents expire. Portfolio: Adds ophthalmology to Alvotech’s primarily immunology-focused biosimilar line-up, diversifying revenue sources. Capital markets: Incorporation into existing F-3 shelves preserves financing flexibility to fund launch costs. Risk: Final approval and competitive pricing dynamics remain open questions, but today’s news skews clearly positive.

Portfolio Manager

TL;DR: Milestone is positive but not yet cash-generating; watch for final EC decision and launch timing.

Impact: Regulatory clearance in Europe would add a new growth pillar; however, the filing lacks guidance on market entry, manufacturing scale-up, or expected margin profile. Liquidity: Continued use of shelf registrations signals potential capital raises, which could dilute shareholders. Overall, the announcement is incremental yet strategically significant, meriting a modest portfolio overweight until commercial visibility improves.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-41421

Alvotech
(Translation of registrant's name into English)

9, Rue de Bitbourg,
L-1273 Luxembourg,
Grand Duchy of Luxembourg
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Incorporation by Reference

This Report on Form 6-K (this “Report”) of Alvotech (the “Company”), excluding Exhibit 99.1 attached hereto, shall be deemed to be incorporated by reference into the Company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684) and the Company’s registration statement on Form S-8 (File No. 333-266881) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 99.1 to this Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Press Release

On June 23, 2025, Alvotech issued a press release announcing that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg) . A copy of the Press Release is furnished herewith as exhibit 99.1.

EXHIBIT INDEX 

Exhibit Number		Description
99.1		Press Release dated June 23, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Alvotech
		(Registrant)
Date: June 23, 2025		/s/ Tanya Zharov
		Tanya Zharov
		General Counsel

FAQ

What did EMA’s CHMP decide regarding Alvotech’s AVT06?

The CHMP adopted a positive opinion recommending approval of AVT06, Alvotech’s proposed biosimilar to Eylea®.

When was the CHMP decision for AVT06 announced by ALVO?

Alvotech announced the decision in a press release dated 23 June 2025.

What reference product is AVT06 a biosimilar to?

AVT06 is a proposed biosimilar to Eylea® (aflibercept 2 mg).

Is the 6-K filing incorporated into Alvotech’s existing registration statements?

Yes. Except for Exhibit 99.1, the report is incorporated by reference into four Form F-3 shelves and one Form S-8.

Does this filing guarantee EMA approval for AVT06?

No. A CHMP positive opinion is encouraging but final approval by the European Commission is still required.